NYSE · STVN
Healthcare · Medical - Instruments & Supplies
$21.43
Up+$0.40 (+1.90%)
Updated Sep 1, 2026, 5:43 AM
SID Score
5.3/10
Composite research score
Smart Money
56/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
STVN closed at $21.43 after 21 trading sessions, up 4.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $21.80 | $21.80 | $20.93 | $21.43 | 335.72K |
| Aug 28, 2026 | $22.23 | $22.26 | $20.86 | $21.03 | 344.07K |
| Aug 27, 2026 | $22.28 | $22.6399 | $22.06 | $22.30 | 306.26K |
| Aug 26, 2026 | $22.56 | $23.00 | $22.25 | $22.38 | 499.24K |
| Aug 25, 2026 | $22.24 | $23.08 | $22.00 | $22.70 | 204.6K |
| Aug 24, 2026 | $22.45 | $23.18 | $22.27 | $22.27 | 1.31M |
| Aug 21, 2026 | $22.40 | $22.68 | $22.195 | $22.60 | 291.49K |
| Aug 20, 2026 | $21.58 | $22.40 | $21.51 | $22.35 | 384.38K |
| Aug 19, 2026 | $21.55 | $21.80 | $21.2494 | $21.71 | 463.64K |
| Aug 18, 2026 | $21.02 | $21.34 | $21.02 | $21.20 | 477.1K |
| Aug 17, 2026 | $21.21 | $21.51 | $20.87 | $21.26 | 560.18K |
| Aug 14, 2026 | $21.46 | $21.5505 | $20.97 | $21.06 | 445.36K |
| Aug 13, 2026 | $21.24 | $21.61 | $20.95 | $21.52 | 571.5K |
| Aug 12, 2026 | $21.05 | $21.40 | $20.59 | $21.25 | 622.25K |
| Aug 11, 2026 | $20.35 | $21.26 | $20.35 | $21.05 | 446.31K |
| Aug 10, 2026 | $19.99 | $20.80 | $19.99 | $20.58 | 501.63K |
| Aug 7, 2026 | $20.05 | $20.42 | $19.95 | $20.27 | 306.4K |
| Aug 6, 2026 | $19.99 | $20.30 | $19.799 | $20.29 | 386.41K |
| Aug 5, 2026 | $19.76 | $20.64 | $19.76 | $20.10 | 414.56K |
| Aug 4, 2026 | $20.10 | $20.42 | $19.00 | $19.65 | 1.02M |
| Aug 3, 2026 | $19.74 | $20.85 | $19.74 | $20.59 | 786.54K |
The latest Smart Investors Daily articles mentioning STVN.
STVN research
Company profile and research snapshot.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 16, 2026 | TD Cowen | Buy | — |
| Mar 6, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 5, 2026 | Citigroup | Buy | — |
| Mar 5, 2026 | Keybanc | Overweight | — |
| Dec 2, 2025 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
SeekingAlpha · Aug 29, 2026
Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform. Learn why STVN stock is a buy.
Benzinga · Aug 11, 2026
Revealing a significant insider sell on August 10, Marco Lago Dal, Chief Financial Officer at Stevanato Group (NYSE:STVN), as per the latest SEC filing. What Happened: Dal's recent Form 4 filing with the U.S.
SeekingAlpha · Aug 4, 2026
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsLisa Miles - Chief Communications & Investor Relations...
Benzinga · Aug 4, 2026
Stevanato Group (NYSE:STVN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STVN.
